ArticleFrontiers in oncology2022

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report.

Mingrui Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.